Medline Industries Set to Raise Over $5 Billion in 2025 IPO, Sources Confirm

Medline Industries Eyes $5 Billion IPO in 2025, Sources Reveal

Medline Industries, one of the world’s largest medical supply companies, is preparing for a significant stock market debut in 2025, with plans to raise over $5 billion in its U.S. initial public offering (IPO). Sources familiar with the matter have confirmed that the Northfield, Illinois-based company, backed by private equity firms Blackstone, Carlyle, and Hellman & Friedman, is aiming for a valuation of around $50 billion. This IPO could take place as early as the second quarter of 2025, although market conditions may affect the timeline.

Medline, which manufactures and distributes essential medical products such as surgical instruments, gloves, and laboratory devices used in hospitals worldwide, has invited several investment banks to pitch for lead roles in what is expected to be one of the biggest IPOs of next year.

Medline’s IPO Plans Amid Market Volatility

Medline’s upcoming IPO signals a recovery in the market for initial public offerings, which faced significant volatility in recent years. After a slowdown in IPOs due to market uncertainty, the launch of major public offerings like Medline’s is anticipated to reignite investor interest in 2025. Other notable companies, including AI cloud platform provider CoreWeave and cybersecurity firm SailPoint, are also preparing for their IPOs next year, according to sources.

A History of Growth and Private Equity Backing

Founded in 1966 by brothers James and Jon Mills, Medline went public in 1972, before being taken private again by the Mills family. In 2021, the company was acquired for $34 billion by a group of private equity firms led by Blackstone, Carlyle, and Hellman & Friedman. Under private equity ownership, Medline has expanded its reach globally, employing around 43,000 people in more than 100 countries, and generating over $23 billion in annual sales.

Last year, longtime CEO Charlie Mills retired, with company veteran Jim Boyle taking over as the new chief executive. Boyle’s leadership marks a new chapter for Medline as it prepares to re-enter the public market.

Medline’s Market Position and Future Outlook

Medline’s decision to pursue an IPO is indicative of its strength in the medical supply industry. The company’s expansive product portfolio and extensive global footprint make it a key player in the healthcare sector. Its IPO will likely be one of the standout moments in the 2025 market and could pave the way for other healthcare and medical supply companies to go public.

As the company prepares to list, the eyes of investors and industry watchers will be on Medline, with its IPO expected to draw significant attention from institutional and retail investors alike.

Conclusion: A Major Milestone for Medline

Medline’s planned IPO marks a pivotal moment in the company’s journey. As it aims to raise over $5 billion and secure a $50 billion valuation, Medline will solidify its position as a global leader in medical supplies. The company’s upcoming stock market debut will not only reshape its future but also set the tone for the healthcare sector’s presence on the public market in 2025. With strong backing from private equity and a well-established market presence, Medline’s IPO is poised to be one of the most highly anticipated offerings of the year.